Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foritinib succinate - Fochon Pharma

Next Previous
Drug Profile

Foritinib succinate - Fochon Pharma

Alternative Names: Furuitini succinate; SAF 189; SAF-189s

Latest Information Update: 05 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Fochon Pharmaceutical; Shanghai Institute of Materia Medica
  • Developer Shanghai Fosun Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 07 Sep 2024 Adverse events and efficacy data from phase III trial in Non-small cell lung cancer presented at the 25th World Conference on Lung Cancer (WCLC-2024)
  • 20 Oct 2023 Efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress 2023 (ESMO-2023)
  • 10 May 2023 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO), prior to May 2023 (Fosun Pharmaceutical pipeline, May 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top